Trending...
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- Airwavz Solutions Appoints Monte Dube to Market Advisory Board to Strengthen Healthcare Wireless Strategy
METAvivor Research and Support announces six additional new grant awards for metastatic breast cancer research totaling $1,200,000. 2019 was a banner year for METAvivor and is a result of increasing awareness of metastatic breast cancer These grants hold promise for future treatments and therapies that will one day, change metastatic breast cancer from a terminal disease to one that is chronic yet manageable.
ANNAPOLIS, Md. - illiNews -- METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), announces six additional grant awards, bringing the 2019 grant award total to $6,200,000. The research grants will enhance the understanding of metastatic breast cancer, help improve current treatments and develop greatly needed therapeutic options to combat this complicated disease.
Metastatic breast cancer (also known as Stage IV or advanced stage cancer) is the spread of breast cancer to other parts of the body -- most commonly to the bones, liver, lungs and/or brain. Approximately 30% of breast cancer patients metastasize, with the mean survival after diagnosis being 33 months. In the US, only 2-5% of all cancer research funds are dedicated to Stage IV cancer research – yet 98% of all breast cancer deaths are caused by a metastasis.
"When we announced our grants in December, we were thrilled to have our largest grant award total since METAvivor's founding. Once we totaled our end of the year donations for research, we were able to award an additional six grants bringing this year's research award total to 38 grants and a grand total of $6.2 million" said Michael Kovarik, the new President of METAvivor's Board of Directors "We are humbled that our supporters have helped us exceed our goal for funding stage IV metastatic breast cancer in 2019 and we look forward to an even higher amount of awarded grants in 2020."
More on illi News
The additional METAvivor grant awards are Translational Research Grant awards program is targeted at career metastasis researchers with a total award of up to $200,000 per grant for 2019.
"Research is our number one priority. It is imperative we increase research funding for stage IV metastatic breast cancer so that we can find life extending treatments. We continue to lose 114 people every day to metastatic breast cancer." Said Kovarik. "The hope is that the vital research that is being funded will help fulfill the promise to transform metastatic breast cancer from a terminal disease into a chronic, manageable condition." METAvivor sends a hearty thank you to the donors, fundraisers, research partners, sponsors and the breast cancer community for helping exceed the research goal for 2019.
BELOW ARE THE SIX ADDITIONAL METASTATIC RESEARCH GRANT RECIPIENTS:
METAVIVOR TRANSLATIONAL RESEARCH AWARDS
Nancy Lin, MD - Dana-Farber Cancer Institute - Overcoming Treatment Resistance in Breast Cancer Brain Metastases
Bolin Liu, MD - Department of Genetics Stanley S. Scott Cancer Center School of Medicine Louisiana State University Health Sciences Center - IGF-2 in Herceptin refractory HER2-positive breast cancer
Paul Lockman, PhD - West Virginia University -Timing of radiotherapy and chemotherapy to improve drug effect in brain metastases of breast cancer
Presented by 2019 NYFW + #Cancerland in memory of Champagne Joy - Deepali Sachdev, BSc,MSc, PhD Regents University - Development of natural killer cell based tri-specific killer engagers (TriKEs) as novel immunotherapy for metastatic breast cancer
More on illi News
Robert Weinberg, PhD Whitehead Institute for Biomedical Research - Mechanisms of Acquired Adaptation of Disseminated Breast Cancer Cells
Fei Xing, PhD Wake Forest University Treating breast cancer brain metastasis with immune checkpoint inhibitor and c-Met targeting agent
ABOUT METAVIVOR
METAvivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009. The organization's main focus is to fund critical research that will lead to advances in treatment options, quality of life and survival for patients diagnosed with MBC. Since 2009, METAvivor has awarded 106 research grants totaling $13.6 million. METAvivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding MBC research, and 100% of all donations go to fund research.
METAvivor also raises awareness of MBC, provides support for people living with this disease, and offers opportunities for others to help make a difference for the metastatic community. METAvivor has gained a rapidly growing following within the breast cancer community and has become a leader in its field.
Visit us at www.METAvivor.org, and follow us on Facebook, Twitter and Instagram.
Metastatic breast cancer (also known as Stage IV or advanced stage cancer) is the spread of breast cancer to other parts of the body -- most commonly to the bones, liver, lungs and/or brain. Approximately 30% of breast cancer patients metastasize, with the mean survival after diagnosis being 33 months. In the US, only 2-5% of all cancer research funds are dedicated to Stage IV cancer research – yet 98% of all breast cancer deaths are caused by a metastasis.
"When we announced our grants in December, we were thrilled to have our largest grant award total since METAvivor's founding. Once we totaled our end of the year donations for research, we were able to award an additional six grants bringing this year's research award total to 38 grants and a grand total of $6.2 million" said Michael Kovarik, the new President of METAvivor's Board of Directors "We are humbled that our supporters have helped us exceed our goal for funding stage IV metastatic breast cancer in 2019 and we look forward to an even higher amount of awarded grants in 2020."
More on illi News
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- HeyGears Achieves Breakthrough in Multi-Material Resin 3D Printing, Overcoming Bottlenecks in Dental Manufacturing
- Levata Acquires Logiscenter to Accelerate Growth in Enterprise IT and Data Capture Solutions
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
The additional METAvivor grant awards are Translational Research Grant awards program is targeted at career metastasis researchers with a total award of up to $200,000 per grant for 2019.
"Research is our number one priority. It is imperative we increase research funding for stage IV metastatic breast cancer so that we can find life extending treatments. We continue to lose 114 people every day to metastatic breast cancer." Said Kovarik. "The hope is that the vital research that is being funded will help fulfill the promise to transform metastatic breast cancer from a terminal disease into a chronic, manageable condition." METAvivor sends a hearty thank you to the donors, fundraisers, research partners, sponsors and the breast cancer community for helping exceed the research goal for 2019.
BELOW ARE THE SIX ADDITIONAL METASTATIC RESEARCH GRANT RECIPIENTS:
METAVIVOR TRANSLATIONAL RESEARCH AWARDS
Nancy Lin, MD - Dana-Farber Cancer Institute - Overcoming Treatment Resistance in Breast Cancer Brain Metastases
Bolin Liu, MD - Department of Genetics Stanley S. Scott Cancer Center School of Medicine Louisiana State University Health Sciences Center - IGF-2 in Herceptin refractory HER2-positive breast cancer
Paul Lockman, PhD - West Virginia University -Timing of radiotherapy and chemotherapy to improve drug effect in brain metastases of breast cancer
Presented by 2019 NYFW + #Cancerland in memory of Champagne Joy - Deepali Sachdev, BSc,MSc, PhD Regents University - Development of natural killer cell based tri-specific killer engagers (TriKEs) as novel immunotherapy for metastatic breast cancer
More on illi News
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Startup Born of CTE + Depression Launches Japandi Supply House
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Sylver's Debut Book Reveals Massive Industry Oversight
Robert Weinberg, PhD Whitehead Institute for Biomedical Research - Mechanisms of Acquired Adaptation of Disseminated Breast Cancer Cells
Fei Xing, PhD Wake Forest University Treating breast cancer brain metastasis with immune checkpoint inhibitor and c-Met targeting agent
ABOUT METAVIVOR
METAvivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009. The organization's main focus is to fund critical research that will lead to advances in treatment options, quality of life and survival for patients diagnosed with MBC. Since 2009, METAvivor has awarded 106 research grants totaling $13.6 million. METAvivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding MBC research, and 100% of all donations go to fund research.
METAvivor also raises awareness of MBC, provides support for people living with this disease, and offers opportunities for others to help make a difference for the metastatic community. METAvivor has gained a rapidly growing following within the breast cancer community and has become a leader in its field.
Visit us at www.METAvivor.org, and follow us on Facebook, Twitter and Instagram.
Source: Metavivor Research and Support, Inc.
Filed Under: Business
0 Comments
Latest on illi News
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Digi 995 Expands Its Universe: All Three Novels Now Available in Paperback Worldwide
- Chicago: Mayor Brandon Johnson on Track to Hit Summer Youth Employment Goal with Almost 29,000 Young People Hired for Third Consecutive Year of Expanded Opportunities
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Digi 995 Audiobooks Officially Released: Fans Can Now Listen to the Complete Trilogy
- Naperville: Two Men Charged with Aggravated Street Racing
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Celebrate National Beef Tallow Day with South Chicago Packing
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams